Luminor Medical Devices
Luminor Medical Devices
  • Home
  • About Us
  • Our Products
  • Contact Us
  • SmartHeart
  • More
    • Home
    • About Us
    • Our Products
    • Contact Us
    • SmartHeart
  • Home
  • About Us
  • Our Products
  • Contact Us
  • SmartHeart

What is essential-pro?

Paclitaxel eluting coronary balloon dilatation catheter
The novel reliable DCB

ESSENTIAL PRO FEATURES

High pushability

Improved transition lumen

Improved visibility

Pt/Ir MRO markers

Excellent trackability

Hydrax plus

Not all DCB are same

Coating technology

  • TransferTech, the iVascular proprietary nanotechnology that Has an ultrathin coating thanks to the nanodrop technology used to coat the balloons.
  • Ensures a durable coating due to its multilayer technology, with minimum drug loss during navigation.
  • Ensures a uniform artery treatment.

Formulation

Ensure low drug loss, quick transfer and more retention time in the artery: 

  • 20% excipient
  • 80% paclitaxel


Spray NanoTechnology

Ultrasound pule to break the solution into uniform nanodrops

Spray dosage system that provides a homogenous drug distribution.

Ultra thin multilayer coating

Minimizes drug loss while navigating to the lesion, reduce the coating stress and the risk of cracking.

Dry-off technology

Process to create paclitaxel microcrystals, which can be transferred fast and maintain more time.

CLINICAL SUPPORT

Description

  • Device: Essential-pro
  • Number of patients: 71
  • Followup: 12-month
  • Type of Lesions: de – novo lesions in small coronary vessels


Conclusion: the use of the Essential for treating de-novo coronary lesions in small coronary vessels was safe and associated with low rates of clinical events at the 12-month follow-up.

EffPac 5-year has been presented at LINC 2022 by Prof Ulf Teichgräber.


Main Investigator: Dr Josep Rodés-Cabau (PI), Quebec Heart and Lung Institute (Quebec, CAN)

Description

  • Device: Essential-pro
  • Number of patients: 33
  • Followup:  24-month
  • Type of Lesions: DES and BMS in-stent restenosis


In this study, the drug-coated balloon Essential showed a good efficacy in the treatment of ISR (mostly of DES) in terms of OCT and QCA assessment, which appear to be comparable to the provided by other drug-coated balloons well supported by clinical evidence.


Main Investigator: José M. de la Torre Hernandez, Universitary Hospital Marqués de Valdecilla, (Santander, SPA)

Luminor Medical Devices

Copyright © 2025 Luminor Medical Devices - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept